References
- Bai L, Zhang DS, Wu WJ, et al (2015). Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Med Oncol, 32, 469.
- Chiron M, Bagley RG, Pollard J (2014). Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther, 13, 1636-44. https://doi.org/10.1158/1535-7163.MCT-13-0753
- Chiron M, Bagley RG, Pollard J, et al (2014). Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther, 13, 1636-44. https://doi.org/10.1158/1535-7163.MCT-13-0753
- Common Terminology Criteria for Adverse Events v4.0 (CTCAE 2009). U.S department of health and human services.
- Do K, Cao L, Kang Z, et al (2015). A phase II study of sorafenib combined with cetuximab in EGFR-expressing, KRAS-mutated metastatic colorectal cancer. Clin Colorectal Cancer, 14, 154-61. https://doi.org/10.1016/j.clcc.2015.02.007
- Garcia-Alfonso P, Ferrer A, Gil S, et al (2015). Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol, 10, 453-65. https://doi.org/10.1007/s11523-015-0362-0
- Grothey A, Van Cutsem E, Sobrero A, et al (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 38, 303-12.
- Jitawatanarat P, Wee W (2013). Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol, 4, 231-8.
- Lee JJ, Chu E (2014). Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer, 13, 135-44. https://doi.org/10.1016/j.clcc.2014.02.001
- Lim KG (2014). A review of colorectal cancer research in malaysia. Med J Malaysia, 69, 23-32.
- Majid N, Ghissassi I, Mrabti H, et al (2015). Bevacizumab in clinical practice. Gulf J Oncol, 1, 33-7.
- Malaysia cancer statistics- Data and figure (2007). National Cancer Registry Report.
- Muhammad S, Jiang Z, Liu Z, Kaur K, Wang X (2013). The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. J Gastrointest Oncol, 4, 72-81.
- Nishino M, Jagannathan JP, Ramaiya NH, et al (2010). Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgeno. 195, 281-9. https://doi.org/10.2214/AJR.09.4110
- Norwati D, Harmy MY, Norhayati MN, Amry AR (2014). Colorectal cancer screening practices of primary care providers: results of a national survey in Malaysia. Asian Pac J Cancer Prev, 15, 2901-4. https://doi.org/10.7314/APJCP.2014.15.6.2901
- Papadopoulos N, Martin J, Ruan Q (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 15, 171-85. https://doi.org/10.1007/s10456-011-9249-6
- Passardi A, Nanni O, Tassinari D, et al (2015). Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol, 26, 1201-7. https://doi.org/10.1093/annonc/mdv130
- Patel A, Sun W (2014). Ziv-aflibercept in metastatic colorectal cancer. Biologics, 8, 13-25.
- Pourhoseingholi MA (2012). Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol, 4, 68-70. https://doi.org/10.4251/wjgo.v4.i4.68
- Product Information (2012). ZALTRAP(R) intravenous injection, ziv-aflibercept intravenous injection. sanofi-aventis U.S.LLC (per FDA), Bridgewater, NJ.
- Syed YY, McKeage K (2015). Aflibercept: a review in metastatic colorectal cancer. Drugs, 75, 1435-45. https://doi.org/10.1007/s40265-015-0444-4
- Tang PA, Moore MJ (2013). Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and+ interpretations. Therap Adv Gastroenterol, 6, 459-73. https://doi.org/10.1177/1756283X13502637
- Van Cutsem E, Tabernero J, Lakomy R, et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol, 30, 3499-506. https://doi.org/10.1200/JCO.2012.42.8201
- Wong NA, Gonzalez D, Salto-Tellez M (2014). RAS testing of colorectal carcinoma-a guidance document from the association of clinical pathologists molecular pathology and diagnostics group. J Clin Pathol, 67, 751-7. https://doi.org/10.1136/jclinpath-2014-202467
- Yoshida M, Muro K, Tsuji A (2015). Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer, 51, 935-41. https://doi.org/10.1016/j.ejca.2015.03.007
Cited by
- Antineoplastics/folinic acid vol.1642, pp.1, 2017, https://doi.org/10.1007/s40278-017-27211-3
- Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy vol.22, pp.5, 2018, https://doi.org/10.1188/18.CJON.555-560